Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-co

Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-compar

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market s

CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Can

Final meeting minutes reflect alignment with Health Canada on the planned content and structure of t

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by a

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by a

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in A

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnol

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands i

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE,

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing si

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) has been given a consensus rating of "

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-

Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further

Notifications have no immediate effect on the listing or trading of the Company's securities on 

Notifications have no immediate effect on the listing or trading of the Company's securities on Nasd

NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.44) per share which missed th

2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program i

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent c

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnolo

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnol

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

NeuroSense Therapeutics Ltd. ("NeuroSense") today announced that the database has been locke

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnolo

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, w

NeuroSense Therapeutics Ltd. (the "Company") Reports Additional Clinical Data from its Phase

Financing at 40% premium to market price provides near-term bridge to anticipated milestonesCAMBRIDG